Atosiban – A Specific Evolution for the Management of Preterm Labour

February 16, 2007

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

Available for download in Word Document format

Why Treat Preterm Labour?

Preterm labour remains the leading cause of neonatal mortality and morbidity. The current Epicure study in the UK suggests that almost 50% of babies born at 23-25 weeks gestation will have significant long term handicap. At the very least, delaying delivery for 48 hours can allow antenatal steroid treatment which reduces the incidence of neonatal respiratory distress syndrome and mortality.

Who to Treat for Preterm Labour

Risk factors. The presence of ‘risk factors’ in the woman’s history could theoretically be used to select a group of women for treatment.. Probably the most efficient risk factor known is a previous preterm birth, which is associated with about a three-fold increase in the risk of a further preterm delivery1. However, this only raises the risk to about 30% and is not applicable to nulliparae. In women in their first pregnancies, a low body mass index is one of the better predictors1,2 but the relative risk is only about 2 in women with spontaneous ovulation (the preterm delivery rate is up to 50% in underweight women who require ovulation induction to conceive2, but this is a very small group). Other risk factors such as minority ethnic origin, poor socio-economic status, and working during pregnancy have a significant association with preterm labour, but the relative risk is only about 1.5. There have been many attempts to combine the various risk factors into a ‘risk score’, but they fail to identify even half the women who actually deliver preterm. Predictive techniques. In continental Europe, regular digital cervical examination has been a popular approach to detecting women at high risk of preterm labour. However, a recent prospective randomised trial of 5602 women failed to show either an increase in applied interventions to prevent preterm labour, or a reduction in the preterm delivery rate3. Ultrasound examination of the cervix has suggested that with cervical lengths less than the 10% percentile (2.5cm) at 24 and 28 weeks, the relative risk of preterm birth is increased4. The presence of funnelling, which was 5.9% and 8.6% at 24 and 28 weeks respectively, was also a risk factor for preterm birth. Active measures to produce ‘funnelling’ as a test of cervical competence have also been described5; 5; 6; however, evidence of the value of the technique is currently weak. Monitoring of uterine activity, for example with home tocographs, has not proved to be efficacious7-11. The finding of fetal fibronectin in vaginal secretions is associated with a substantial risk of preterm labour12-17. However, even sampling at regular two weekly intervals was found in some studies to be too non-specific for reliable prediction18. Fibronectin screening alone has yet to be shown to have any impact on the preterm delivery rate, perhaps because of the perennial problem, lack of an effective intervention19. Currently, screening for bacterial vaginosis is undergoing a similar evaluation20-22.

Diagnosis. This remains difficult. Progressive dilatation of the cervix is probably the only conclusive proof of labour, even demonstration of amniotic fluid draining per vaginam is not associated with progressive labour in about 20% of cases. Keirse and colleagues’ meta-analysis of 16 trials of betamimetics in ‘preterm labour’23 showed that in the untreated group, 412 of 660 (62%) did not deliver within 48 hours and 249 of 720 women (34.5%) did not deliver until term. Thus, any treatment given when preterm labour is diagnosed is likely to be unnecessary in about half the cases. In any case, in many preterm labours, tocolysis is inappropriate. In Tucker et al’s study of 13,119 singleton births24, there were 1445 preterm births (11%) but 630 (44%) of these were greater than 34 weeks gestation and treatment was therefore not indicated. 241 women had preterm premature rupture of membranes, and tocolysis was deemed inappropriate because of the risk of infection. In 238 women, birth was appropriate (26% had raised blood pressure, 22% had an intrauterine death, 16% had intrauterine growth retardation and 189 were 3cm or more dilated). Only in 147 was tocolysis possible, i.e. 5% of the 815 babies < 35 weeks, or just about 1% of total births.

Current tocolytic therapy. Older tocolytics such as alcohol and isoxuprine hydrochloride have now been abandoned as largely ineffective and with too many side effects. All currently used tocolytics also have important side effects. The risks of tocolysis with b agonists include fluid overload and pulmonary oedema, myocardial ischaemia, hyperglycaemia, hypokalaemia and death25-35. With indomethacin, the risks are both maternal (peptic ul ceration, gastrointestinal bleeding, thrombocytopaenia, and allergic reactions) and fetal (pulmonary hypertension secondary to premature closure of the ductus arteriosus, persistent non-closure of the ductus post-delivery with resistance to further indomethacin therapy, necrotising enterocolitis and small bowel perforation, periventricular and intraventricular haemorrhage, an increase in respiratory distress syndrome and bronchopulmonary dysplasia, and impaired renal function36-47). In the USA, magnesium sulphate is widely used and this can cause adult respiratory distress syndrome, respiratory depression, hypothermia, paralytic ileus and cardiac arrest, and osteoporosis as well as fetal bradycardia and loss of heart rate variability48-51. It also has a low therapeutic ratio (low ratio between effective and toxic effect52), and may increase neonatal mortality53. Calcium channel blockers are also used for tocolysis, but an obvious side-effect is that they cause significant hypotension. Their maternal side-effect profile is better than beta sympathomimetics54 but effects on the fetus have caused concern55; 56. It has been suggested that sublingual nifedipine should be removed from the market57. Of particular concern is the interaction of calcium channel blockers with magnesium sulphate, being reported as causing respiratory failure58; 59, colonic pseudo-obstruction60, and severe vulval oedema61.

Need for a new tocolytic. It is evident from the above that an effective tocolytic that had few or no side-effects would be extremely valuable.

References:

Reference List

1. Mercer BM, Goldenberg RL, Das A, et al. The preterm prediction study: a clinical risk assessment system. Am J Obstet Gynecol 1996;174:1885-1895.

2. van der Spuy ZM, Steer PJ, McCusker M, Steele SJ, Jacobs HS. Outcome of pregnancy in underweight women after spontaneous and induced ovulation. BMJ 1988;. 296:962-965.

3. Beukens P, Alexander S, Boutsen M, et al. Randomised controlled trial of routine cervical examinations in pregnancy. Lancet 1994;344:841-844.

4. Iams JD, Johnson FF, Sonek J, Sachs L, Gebauer C, Samuels P. Cervical competence as a continuum: a study of ultrasonographic cervical length and obstetric performance. Am J Obstet Gynecol 1995;172:1097-1103.

5. Guzman ER, Rosenberg JC, Houlihan C, Ivan J, Waldron R, Knuppel R. A new method using vaginal ultrasound and transfundal pressure to evaluate the asymptomatic incompetent cervix. Obstet Gynecol 1994;83:248-252.

6. Guzman ER, Pisatowski DM, Vintzileos AM, et al. A comparison of ultrasonographically detected cervical changes in response to transfundal pressure, coughing, and standing in predicting cervical incompetence. Am J Obstet Gynecol 1997;177:660-665.

7. Iams JD, Johnson FF, O’Shaughnessy RW, West LC. A prospective random trial of home uterine activity monitoring in pregnancies at increased risk of preterm labor. Am J Obstet Gynecol 1987;157:638-643.

8. Iams JD. Randomized controlled trials of home uterine activity monitoring: a review and critique [letter; comment]. Obstet Gynecol 1992;79:1052-1053.

9. Iams JD. Current status of home uterine activity monitoring. Clinical Obstetrics & Gynecology 1995;38:771-779.

10. Grimes DA, Schulz KF. Randomized controlled trials of home uterine activity monitoring: a review and critique. Obstet Gynecol 1992;79 :137-142.

11. Colton T, Kayne HL, Zhang Y, Heeren T. A metaanalysis of home uterine activity monitoring. Am J Obstet Gynecol 1995;173:1499-1505.

12. Eriksen NL, Parisi VM, Daoust S, Flamm B, Garite TJ, Cox SM. Fetal fibronectin: a method for detecting the presence of amniotic fluid. Obstetrics.&.Gynecology. 1992;80:451-454.

13. Lockwood CJ, Wein R, Lapinski R, et al. The presence of cervical and vaginal fetal fibronectin predicts preterm delivery in an inner-city obstetric population. Am J Obstet Gynecol 1993;169:798-804.

14. Morrison JC, Allbert JR, McLaughlin BN, Whitworth NS, Roberts WE, Martin RW. Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery. Am J Obstet Gynecol 1993;168:538-542.

15. Nageotte MP, Casal D, Senyei AE. Fetal fibronectin in patients at increased risk for premature birth. Am J Obstet Gynecol 1994;170:20-25.

16. Ahner R, Kiss H, Egarter C, et al. Fetal fibronectin as a marker to predict the onset of term labor and delivery. Am J Obstet Gynecol 1995;172:134-137.

17. Burrus DR, Ernest JM, Veille JC. Fetal fibronectin, interleukin-6, and C-reactive protein are useful in establishing prognostic subcategories of idiopathic preterm labor. Am J Obstet Gynecol 1995;173:1258-1262.

18. Hellemans P, Gerris J, Verdonk P. Fetal fibronectin detection for prediction of preterm birth in low risk women. Br J Obstet Gynaecol. 1995;102:207-212.

19. Goldenberg RL, Mercer BM, Meis PJ, Copper RL, Das A, McNellis D. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. Obstet Gynecol 1996;87:643-648.

20. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 1994;170:1048-59.

21. McGregor JA, French JI, Parker R, et al. Prevention of premature birth by screening and treatment for common genital tract infections: Results of a prospective controlled evaluation. Am J Obstet Gynecol 1995;173:157-167.

22. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ 1994;308:295-298.

23. Keirse M. Betamimetics in preterm labour. In: Keirse M, Renfrew MJ, Neilson JP, Crowther C, eds. The Cochrane Pregnancy and Childbirth database. Oxford: Update Software.

24. Tucker JM, Goldenberg RL, Davis RO, Copper RL, Winkler CL, Hauth JC. Etiologies of preterm birth in an indigent population: is prevention a logical expectation? Obstet Gynecol 1991;77:343-347.

25. Wasserman D, Amitai Y. Hypoglycemia following albuterol overdose in a child. American Journal of Emergency Medicine 1992;10:556-557.

26. van Iddekinge B, Gobetz L, Seaward PG, Hofmeyr GJ. Pulmonary oedema after hexoprenaline administration in preterm labour. A report of 4 cases. South African Med J 1991;79:620-622.

27. Gupta RC, Foster S, Romano PM, Thomas HM. Acute pulmonary edema associated with the use of oral ritodrine for premature labor. Chest 1989;95:479-481.

28. Bloss JD, Hankins GD, Gilstrap LC, Hauth JC. Pulmonary edema as a delayed complication of ritodrine therapy. A case report. J Reprod Med 1987;32:469-471.

29. MacLennan FM, Thomson MA, Rankin R, Terry PB, Adey GD. Fatal pulmonary oedema associated with the use of ritodrine in pregnancy. Case report. Br J Obstet Gynaecol 1985;92:703-705.

30. Marks RJ, De Chazal RC. Ritodrine-induced pulmonary oedema in labour. Successful management using epidural anaesthesia. Anaesthesia 1984;39:1012-1014.

31. Alper M, Cohen WR. Pulmonary edema associated with ritodrine and dexamethasone treatment of threatened premature labor. A case report. J Reprod Med 1983;28:349-352.

32. Mabie WC, Pernoll ML, Witty JB, Biswas MK. Pulmonary edema induced by betamimetic drugs. Southern Medical Journal 1983;76:1354-1360.

33. Felding C, Hasselbach H. Ante-natal pulmonary edema and metabolic acidosis. Postpartum pulmonary embolism in a non-diabetic patient associated with ritodrine and betamethasone administration in premature labor. Acta Obstet Gynecol Scand 1981;60:587-588.

34. Reichman J, Goldman JA. Pulmonary edema after ritodrine infusion for premature labor in a patient with mitral valve disease. Acta Obstet Gynecol Scand 1981;60:87-88.

35. Abramovici H, Lewin A, Lissak A, Palant A. Maternal pulmonary edema occurring after therapy with ritodrine for premature uterine contractions. Acta Obstet Gynecol Scand 1980;59:555

36. Clyman RI, Hardy P, Waleh N, et al. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Amer J Physiol 1999;276:R913-R921

37. Souter D, Harding J, McCowan L, O’Donnell C, McLeay E, Baxendale H. Antenatal indomethacin-adverse fetal effects confirmed. Aust NZ J Obstet Gynaecol 1998;38:11-16.

38. Hammerman C, Glaser J, Kaplan M, Schimmel MS, Ferber B, Eidelman AI. Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Pediatrics 1998;102:E56

39. Van Overmeire B, Slootmaekers V, De Loor J, et al. The addition of indomethacin to betamimetics for tocolysis: any benefit for the neonate? Europ J Obstet Gynecol Reprod Biol 1998;77:41-45.

40. Macones GA, Robinson CA. Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Am J Obstet Gynecol 1997;177:819-824.

41. Vermillion ST, Scardo JA, Lashus AG, Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997;177:256-259.

42. Salokorpi T, Eronen M, von Wendt L. Growth and development until 18 months of children exposed to tocolytics indomethacin or nylidrin. Neuropediatrics 1996;27:174-177.

43. Ben-David Y, Hallak M, Rotschild A, Sorokin Y, Auslender R, Abramovici H. Indomethacin and fetal ductus arteriosus: complete closure after cessation of prolonged therapeutic course. Fetal Diagnosis & Therapy 1996;11:341-344.

44. Iannucci TA, Besinger RE, Fisher SG, Gianopoulos JG, Tomich PG. Effect of dual tocolysis on the incidence of severe intraventricular hemorrhage among extremely low-birth-weight infants. Am J Obstet Gynecol 1996;175:1043-1046.

45. Fejgin MD, Delpino ML, Bidiwala KS. Isolated small bowel perforation following intrauterine treatment with indomethacin. Am J Perinatol 1994;11:295-296.

46. Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Eng J Med 1993;329:1602-1607.

47. Bivins HAJ, Newman RB, Fyfe DA, Campbell BA, Stramm SL. Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor. Am J Obstet Gynecol 1993;169:1065-1070.

48. Cardosi RJ, Chez RA. Magnesium sulfate, maternal hypothermia, and fetal bradycardia with loss of heart rate variability. Obstet Gynecol 1998;92:691-693.

49. Hamersley SL, Landy HJ, O’Sullivan MJ. Fetal bradycardia secondary to magnesium sulfate therapy for preterm labor. A case report. J Reprod Med 1998;43:206-210.

50. Levav AL, Chan L, Wapner RJ. Long-term magnesium sulfate tocolysis and maternal osteoporosis in a triplet pregnancy: a case report. Am J Perinatol 1998;15:43-46.

51. Hill WC, Gill PJ, Katz M. Maternal paralytic ileus as a complication of magnesium sulfate tocolysis. Am J Perinatol 1985;2:47-48.

52. Svigos JM, Robinson JS, Vigneswaran R. Threatened and actual preterm labor, including mode of delivery. In: James DK, Steer PJ, Weiner CP, Gonik B, eds. High risk pregnancy - management options . London: W B Saunders Company Ltd, 1994;151-161.

53. Mittendorf R, Pryde P, Khoshnood B, Lee KS. If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact? Obstet Gynecol 1998;92:308-311.

54. Ray JG. Meta-analysis of Nifedipine versus beta-sympathomimetic agents for tocolysis during preterm labour. J Soc Obstet Gynaecol Can 1998;20:259-269.

55. Blea CW, Barnard JM, Magness RR, Phernetton TM, Hendricks SK. Effect of nifedipine on fetal and maternal hemodynamics and blood gases in the pregnant ewe. Am J Obstet Gynecol 1997;176:922-930.

56. Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993;100:959-961.

57. Waisman GD, Mayorga LM, Camera MI, Vignolo CA, Martinotti A. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia?. Am J Obstet Gynecol 1988;159:308-309.

58. Snyder SW, Cardwell MS. Neuromuscular blockade with magnesium sulfate and nifedipine. Am J Obstet Gynecol 1989;161:35-36.

59. Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol 1994;101:262-263.

60. Pecha RE, Danilewitz MD. Acute pseudo-obstruction of the colon (Ogilvie’s syndrome) resulting from combination tocolytic therapy. Am J Gastroenterol 1996;91:1265-1266.

61. Trice L, Bennert H, Stubblefield PG. Massive vulvar edema complicating tocolysis in a patient with twins. A case report. J Reprod Med 1996;41:121-124.